N/A
N=300
Management of Nausea and Vomiting Chemotherapy-induced in Normandy
Cancer · Nausea · Vomiting
Bottom Line
View on ClinicalTrials.gov: NCT01440465 ↗Enrolled (actual)
300
Serious AEs
0.3%
Results posted
Dec 2025
Primary outcome: Primary: Number of Participants With Acute Nausea and Vomiting — 101 Participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Centre Francois Baclesse
- Primary completion
- Jan 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Acute Nausea and Vomiting |
101 | — |
Summary
The objective of this study was to evaluate the various parameters involved in the occurrence of nausea / vomiting during the first cycle of chemotherapy for solid tumors or hematologic among a group of chemotherapy-naive patients, despite anti standardized-emetics protocols.
Eligibility Criteria
Inclusion Criteria
- Aged over 18 years
- With solid tumors or hematologic in first line chemotherapy, administered intravenously,
- Able to understand the meaning of the questions
- Having given their written consent to participate in the survey.
Exclusion Criteria
This does not concern patients who:
- Do not give their consent for participation
- Do not speak French
- Suffer from cognitive deficits
- Are under therapy
- Must receive a combination of radio-chemotherapy
- Present an occlusive syndrome
- Metastases (s) brain (s) clinically symptomatic (s) or radiologically proven (s) or a (of) tumor (s) brain (s)
- Have been previously treated with chemotherapy
- Present a cons-indication to corticosteroids, with anti-serotonin or NK1 receptor inhibitors
- Pregnant or breastfeeding.
Data sourced from ClinicalTrials.gov (NCT01440465). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.